 | • レポートコード：TPM-NV049 • 出版社/出版日：Transparency Market Research / 2019年10月22日 • レポート形態：英文、PDF、273ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、尿路感染症治療の世界市場について調べ、尿路感染症治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、疾患別（合併症のないUTIおよび合併症のあるUTI）分析、薬物クラス別（キノロン、ベータラクタム、マクロライド、アミノグリコシド、その他）分析、病原体別（大腸菌、緑膿菌、腸球菌、肺炎球菌、黄色ブドウ球菌、その他）分析、感染源別（病院取得型UTIおよびコミュニティ取得型UTI）分析、関連企業情報などをまとめました。 ・尿路感染症治療の市場概要 ・尿路感染症治療の市場動向 ・尿路感染症治療の世界市場規模・予測 ・尿路感染症治療市場：疾患別（合併症のないUTIおよび合併症のあるUTI） ・尿路感染症治療市場：薬物クラス別（キノロン、ベータラクタム、マクロライド、アミノグリコシド、その他） ・尿路感染症治療市場：薬物クラス別（キノロン、ベータラクタム、マクロライド、アミノグリコシド、その他） ・尿路感染症治療市場：感染源別（病院取得型UTIおよびコミュニティ取得型UTI） ・地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争環境・関連企業分析 |
Urinary Tract Infection Treatment Market – Scope of the Study
Transparency Market Research (TMR), in its recently published report, determines the key growth opportunities present in the urinary tract infection treatment market for the forecast period of 2019-2027. The comprehensive study traces the significant trends and recent developments encircling the urinary tract infection treatment landscape. In addition to this, it offers actionable insights into the urinary tract infection treatment market by offering a detailed assessment of the key drivers, restraints, threats, and opportunities.
This detailed study provides an analysis of the demand and supply chain, which offers a brief outlook on the balance of the demand-supply chain in the urinary tract infection treatment market. This comprehensive guide discusses the macroeconomic as well as microeconomic parameters that help in understanding the upward growth trajectory of the urinary tract infection treatment market during the forecast period.
The urinary tract infection treatment market size has been evaluated in terms of value (US$ Mn) and volume (‘000 Units). The information included in this exhaustive research report can aid market players of the urinary tract infection treatment market in determining profitable growth prospects for their business advancement.
Urinary Tract Infection Treatment Market – Key Questions Answered
What are the macroeconomic factors that are impeding the growth of the urinary tract infection treatment market?
What is the prevalence of diseases in the urinary tract infection treatment landscape?
How will the urinary tract infection treatment market evolve during the forecast period?
What are the important distribution channels that gauge the potential growth in the urinary tract infection treatment market?
What are the key challenges deterring the growth of the urinary tract infection treatment market?
Urinary Tract Infection Treatment Market – Research Methodology
Transparency Market Research (TMR) follows a robust approach to derive significant insights into the urinary tract infection treatment market. An in-depth study of the growth opportunities for both, market players and stakeholders, was conducted and evaluated in tandem with the market size of urinary tract infection treatment. Crucial segments of the urinary tract infection treatment market are identified, and their market share is taken into consideration to evaluate the size of the urinary tract infection treatment market during the forecast period. In addition to this, the urinary tract infection treatment market segmentation is used as data points, and key insights from primary respondents and opinion leaders of the urinary tract infection treatment market are taken into consideration to estimate the volume and value. Secondary research includes the study of trade journals, press releases, company annual reports, paid resources, and other publications, to obtain distinguished insights.
Urinary Tract Infection Treatment Market – Segmentation
The comprehensive study on the urinary tract infection treatment market provides a comprehensive analysis of the market attractiveness by offering insights into the key segments. The urinary tract infection treatment market has been segregated on the basis of disease, drug class, pathogen, source of infection, gender, distribution channel, and region. The global study highlights a country-wise analysis to lend incisive insights about the healthcare innovations of urinary tract infection treatments.
Each of the segments included in this report help in gaining crucial insights into the urinary tract infection treatment market. The study on the urinary tract infection treatment market offers historical, current, and futuristic trends influencing its growth.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Urinary Tract Infection Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1 Rise in prevalence of UTI
4.3.1.2. Increase in number of hospital acquired infection
4.3.1.3. Rise in awareness about women’s health
4.3.1.4. Introduction of new diagnostic test
4.3.1.5. Development of new antibiotics
4.3.2. Restraints
4.3.2.1 Introduction of generic drug
4.3.2.2. Patent Expiry
4.3.3. Opportunities
4.4. Global Urinary Tract Infection Treatment Market Analysis and Forecast, 2017–2027
5. Market Outlook
5.1. Epidemiology Overview of UTI by Key Countries (Prevalence, Incidence, Overall Burden)
5.2. Pipeline Analysis
5.3. Overview of Guidelines for Diagnosis & Treatment of UTI’s
5.4. Reimbursement Scenario
5.5. Overview of Multi-Drug Resistance Pathogen and Infections (Infection Types & Prevalence, Most drug resistant Bacterial Strains)
5.6. Advancements in UTI diagnosis (Rapid Action Tests, New Assays in Anti-microbial susceptibility testing, etc.)
6. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Disease
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Disease, 2017–2027
6.3.1. Uncomplicated UTI
6.3.2. Complicated UTI
6.4. Market Attractiveness, by Disease
7. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Drug Class, 2017–2027
7.3.1. Quinolones
7.3.2. Beta-lactams
7.3.3. Macrolides
7.3.4. Aminoglycosides
7.3.5. Others
7.4. Market Attractiveness, by Drug Class
8. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Pathogen
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Pathogen, 2017–2027
8.3.1. E. coli
8.3.2. Pseudomonas aeruginosa
8.3.3. Enterococcus spp
8.3.4. K. pneumoniae
8.3.5. S. aureus
8.3.6. Others
8.4. Market Attractiveness, by Pathogen
9. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Source of Infection
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Source of Infection, 2017–2027
9.3.1. Hospital Acquired UTI
9.3.2. Community Acquired UTI
9.4. Market Attractiveness, by Source of Infection
10. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Gender
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Gender, 2017–2027
10.3.1. Female
10.3.2. Male
10.4. Market Attractiveness, by Gender
11. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Distribution Channel
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Value Forecast, by Distribution Channel, 2017–2027
11.3.1. Retail Pharmacies
11.3.2. Hospital Pharmacies
11.3.3. Online Pharmacies
11.4. Market Attractiveness, by Distribution Channel
12. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Market Value Forecast, by Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness, by Country/Region
13. North America Urinary Tract Infection Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease, 2017–2027
13.2.1. Uncomplicated UTI
13.2.2. Complicated UTI
13.3. Market Value Forecast, by Drug Class, 2017–2027
13.3.1. Quinolones
13.3.2. Beta-lactams
13.3.3. Macrolides
13.3.4. Aminoglycosides
13.3.5. Others
13.4. Market Value Forecast, by Pathogen, 2017–2027
13.4.1. E. coli
13.4.2. Pseudomonas aeruginosa
13.4.3. Enterococcus spp
13.4.4. K. pneumoniae
13.4.5. S. aureus
13.4.6. Others
13.5. Market Value Forecast, by Source of Infection, 2017–2027
13.5.1. Hospital Acquired UTI
13.5.2. Community Acquired UTI
13.6. Market Value Forecast, by Gender, 2017–2027
13.6.1. Female
13.6.2. Male
13.7. Market Value Forecast, by Distribution Channel, 2017–2027
13.7.1. Retail Pharmacies
13.7.2. Hospital Pharmacies
13.7.3. Online Pharmacies
13.8. Market Value Forecast, by Country, 2017–2027
13.8.1. U.S.
13.8.2. Canada
13.9. Market Attractiveness Analysis
13.9.1. By Disease
13.9.2. By Drug Class
13.9.3. By Pathogen
13.9.4. By Source of Infection
13.9.5. By Gender
13.9.6. By Distribution Channel
13.9.7. By Country
14. Europe Urinary Tract Infection Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease, 2017–2027
14.2.1. Uncomplicated UTI
14.2.2. Complicated UTI
14.3. Market Value Forecast, by Drug Class, 2017–2027
14.3.1. Quinolones
14.3.2. Beta-lactams
14.3.3. Macrolides
14.3.4. Aminoglycosides
14.3.5. Others
14.4. Market Value Forecast, by Pathogen, 2017–2027
14.4.1. E. coli
14.4.2. Pseudomonas aeruginosa
14.4.3. Enterococcus spp
14.4.4. K. pneumoniae
14.4.5. S. aureus
14.4.6. Others
14.5. Market Value Forecast, by Source of Infection, 2017–2027
14.5.1. Hospital Acquired UTI
14.5.2. Community Acquired UTI
14.6. Market Value Forecast, by Gender, 2017–2027
14.6.1. Female
14.6.2. Male
14.7. Market Value Forecast, by Distribution Channel, 2017–2027
14.7.1. Retail Pharmacies
14.7.2. Hospital Pharmacies
14.7.3. Online Pharmacies
14.8. Market Value Forecast, by Country/Sub-region, 2017–2027
14.8.1. Germany
14.8.2. U.K.
14.8.3. France
14.8.4. Spain
14.8.5. Italy
14.8.6. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Disease
14.9.2. By Drug Class
14.9.3. By Pathogen
14.9.4. By Source of Infection
14.9.5. By Gender
14.9.6. By Distribution Channel
14.9.7. By Country/Sub-region
15. Asia Pacific Urinary Tract Infection Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Disease, 2017–2027
15.2.1. Uncomplicated UTI
15.2.2. Complicated UTI
15.3. Market Value Forecast, by Drug Class, 2017–2027
15.3.1. Quinolones
15.3.2. Beta-lactams
15.3.3. Macrolides
15.3.4. Aminoglycosides
15.3.5. Others
15.4. Market Value Forecast, by Pathogen, 2017–2027
15.4.1. E. coli
15.4.2. Pseudomonas aeruginosa
15.4.3. Enterococcus spp
15.4.4. K. pneumoniae
15.4.5. S. aureus
15.4.6. Others
15.5. Market Value Forecast, by Source of Infection, 2017–2027
15.5.1. Hospital Acquired UTI
15.5.2. Community Acquired UTI
15.6. Market Value Forecast, by Gender, 2017–2027
15.6.1. Female
15.6.2. Male
15.7. Market Value Forecast, by Distribution Channel, 2017–2027
15.7.1. Retail Pharmacies
15.7.2. Hospital Pharmacies
15.7.3. Online Pharmacies
15.8. Market Value Forecast, by Country/Sub-region, 2017–2027
15.8.1. China
15.8.2. Japan
15.8.3. India
15.8.4. Australia & New Zealand
15.8.5. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
15.9.1. By Disease
15.9.2. By Drug Class
15.9.3. By Pathogen
15.9.4. By Source of Infection
15.9.5. By Gender
15.9.6. By Distribution Channel
15.9.7. By Country/Sub-region
16. Latin America Urinary Tract Infection Treatment Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Disease, 2017–2027
16.2.1. Uncomplicated UTI
16.2.2. Complicated UTI
16.3. Market Value Forecast, by Drug Class, 2017–2027
16.3.1. Quinolones
16.3.2. Beta-lactams
16.3.3. Macrolides
16.3.4. Aminoglycosides
16.3.5. Others
16.4. Market Value Forecast, by Pathogen, 2017–2027
16.4.1. E. coli
16.4.2. Pseudomonas aeruginosa
16.4.3. Enterococcus spp
16.4.4. K. pneumoniae
16.4.5. S. aureus
16.4.6. Others
16.5. Market Value Forecast, by Source of Infection, 2017–2027
16.5.1. Hospital Acquired UTI
16.5.2. Community Acquired UTI
16.6. Market Value Forecast, by Gender, 2017–2027
16.6.1. Female
16.6.2. Male
16.7. Market Value Forecast, by Distribution Channel, 2017–2027
16.7.1. Retail Pharmacies
16.7.2. Hospital Pharmacies
16.7.3. Online Pharmacies
16.8. Market Value Forecast, by Country/Sub-region, 2017–2027
16.8.1. Brazil
16.8.2. Mexico
16.8.3. Rest of Latin America
16.9. Market Attractiveness Analysis
16.9.1. By Disease
16.9.2. By Drug Class
16.9.3. By Pathogen
16.9.4. By Source of Infection
16.9.5. By Gender
16.9.6. By Distribution Channel
16.9.7. By Country/Sub-region
17. Middle East & Africa Urinary Tract Infection Treatment Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Disease, 2017–2027
17.2.1. Uncomplicated UTI
17.2.2. Complicated UTI
17.3. Market Value Forecast, by Drug Class, 2017–2027
17.3.1. Quinolones
17.3.2. Beta-lactams
17.3.3. Macrolides
17.3.4. Aminoglycosides
17.3.5. Others
17.4. Market Value Forecast, by Pathogen, 2017–2027
17.4.1. E. coli
17.4.2. Pseudomonas aeruginosa
17.4.3. Enterococcus spp
17.4.4. K. pneumoniae
17.4.5. S. aureus
17.4.6. Others
17.5. Market Value Forecast, by Source of Infection, 2017–2027
17.5.1. Hospital Acquired UTI
17.5.2. Community Acquired UTI
17.6. Market Value Forecast, by Gender, 2017–2027
17.6.1. Female
17.6.2. Male
17.7. Market Value Forecast, by Distribution Channel, 2017–2027
17.7.1. Retail Pharmacies
17.7.2. Hospital Pharmacies
17.7.3. Online Pharmacies
17.8. Market Value Forecast, by Country/Sub-region, 2017–2027
17.8.1. GCC Countries
17.8.2. South Africa
17.8.3. Rest of Middle East & Africa
17.9. Market Attractiveness Analysis
17.9.1. By Disease
17.9.2. By Drug Class
17.9.3. By Pathogen
17.9.4. By Source of Infection
17.9.5. By Gender
17.9.6. By Distribution Channel
17.9.7. By Country/Sub-region
18. Competition Landscape
18.1. Market Player – Competition Matrix (By Tier and Size of companies)
18.2. Market Share Analysis/Ranking, by Company, 2018
18.3. Company Profiles
18.3.1. Allergan
18.3.1.1. Company Overview
18.3.1.2. Product Portfolio
18.3.1.3. SWOT Analysis
18.3.1.4. Financial Overview
18.3.1.5. Strategic Overview
18.3.2. Bayer AG
18.3.2.1. Company Overview
18.3.2.2. Product Portfolio
18.3.2.3. SWOT Analysis
18.3.2.4. Financial Overview
18.3.2.5. Strategic Overview
18.3.3. Pfizer, Inc.
18.3.3.1. Company Overview
18.3.3.2. Product Portfolio
18.3.3.3. SWOT Analysis
18.3.3.4. Financial Overview
18.3.3.5. Strategic Overview
18.3.4. GlaxoSmithKline plc
18.3.4.1. Company Overview
18.3.4.2. Product Portfolio
18.3.4.3. SWOT Analysis
18.3.4.4. Financial Overview
18.3.4.5. Strategic Overview
18.3.5. Bristol-Myers Squibb Company
18.3.5.1. Company Overview
18.3.5.2. Product Portfolio
18.3.5.3. SWOT Analysis
18.3.5.4. Financial Overview
18.3.6. Johnson & Johnson (Janssen Global Services, LLC)
18.3.6.1. Company Overview
18.3.6.2. Product Portfolio
18.3.6.3. SWOT Analysis
18.3.6.4. Financial Overview
18.3.6.5. Strategic Overview
18.3.7. LUPIN
18.3.7.1. Company Overview
18.3.7.2. Product Portfolio
18.3.7.3. SWOT Analysis
18.3.7.4. Financial Overview
18.3.7.5. Strategic Overview
18.3.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp)
18.3.8.1. Company Overview
18.3.8.2. Product Portfolio
18.3.8.3. SWOT Analysis
18.3.8.4. Financial Overview
18.3.8.5. Strategic Overview
18.3.9. Dr. Reddy’s Laboratories Ltd
18.3.9.1. Company Overview
18.3.9.2. Product Portfolio
18.3.9.3. SWOT Analysis
18.3.9.4. Financial Overview
18.3.10. Almirall, S.A
18.3.10.1. Company Overview
18.3.10.2. Product Portfolio
18.3.10.3. SWOT Analysis
18.3.10.4. Financial Overview
18.3.10.5. Strategic Overview
List of TablesTable 01: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 02: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 03: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 04: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 05: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 06: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 07: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 08: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 09: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 10: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 11: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 12: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 13: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 14: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 15: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 16: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 17: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 18: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 19: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 20: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 21: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 22: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 23: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 24: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 25: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 26: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 27: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 28: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 29: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 30: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 31: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 32: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 33: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 34: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 35: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 36: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 37: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 38: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 39: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 40: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 41: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 42: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027